NEVVI Medicare utilization intelligence
Compare this code with others

Jump to the result views

J0174 Injection, lecanemab-irmb, 1 mg HCPCS · Treatment
Classification Treatment › Injections and Infusions (nononcologic) › Injection - Monoclonal Antibodies (CMS RBCS)
First observed 2023
National scale 65.37M services · est. ▲ 3374.2% YoY · 6,300 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 31.38M observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window · National figures — the AZ market is below
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary